JP2023538366A5 - - Google Patents
Info
- Publication number
- JP2023538366A5 JP2023538366A5 JP2023511947A JP2023511947A JP2023538366A5 JP 2023538366 A5 JP2023538366 A5 JP 2023538366A5 JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023538366 A5 JP2023538366 A5 JP 2023538366A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- sdcdr3
- sdcdr1
- sdcdr2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066565P | 2020-08-17 | 2020-08-17 | |
| US63/066,565 | 2020-08-17 | ||
| PCT/US2021/046217 WO2022040128A2 (en) | 2020-08-17 | 2021-08-17 | Constrained conditionally activated binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538366A JP2023538366A (ja) | 2023-09-07 |
| JP2023538366A5 true JP2023538366A5 (enExample) | 2024-08-22 |
| JP7832926B2 JP7832926B2 (ja) | 2026-03-18 |
Family
ID=77655705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511947A Active JP7832926B2 (ja) | 2020-08-17 | 2021-08-17 | 制約され、条件付きで活性化された結合タンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240026011A1 (enExample) |
| EP (1) | EP4196503A2 (enExample) |
| JP (1) | JP7832926B2 (enExample) |
| KR (1) | KR20230048146A (enExample) |
| CN (1) | CN116419925A (enExample) |
| AR (1) | AR123266A1 (enExample) |
| AU (1) | AU2021329290A1 (enExample) |
| CA (1) | CA3191431A1 (enExample) |
| CL (1) | CL2023000477A1 (enExample) |
| CO (1) | CO2023002164A2 (enExample) |
| EC (1) | ECSP23018458A (enExample) |
| IL (1) | IL300598A (enExample) |
| MX (1) | MX2023002002A (enExample) |
| PE (1) | PE20230856A1 (enExample) |
| TW (1) | TW202214707A (enExample) |
| WO (1) | WO2022040128A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2019051102A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| WO2023164551A1 (en) * | 2022-02-23 | 2023-08-31 | Takeda Pharmaceutical Company Limited | Conditionally bispecific binding proteins |
| WO2024040220A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding fusion proteins |
| WO2024040228A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding proteins |
| CA3266080A1 (en) * | 2022-09-07 | 2024-03-14 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | ANTI-TROP2/EGFR ANTIBODIES AND THEIR USES |
| KR20250131817A (ko) * | 2023-01-05 | 2025-09-03 | 하푼 테라퓨틱스, 인크. | 암 치료를 위한 trop2 표적화 삼중특이적 단백질 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| TW202302631A (zh) | 2016-03-08 | 2023-01-16 | 日商武田藥品工業股份有限公司 | 可誘導性結合蛋白和使用方法 |
| WO2019051102A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
-
2021
- 2021-08-17 US US18/021,730 patent/US20240026011A1/en active Pending
- 2021-08-17 IL IL300598A patent/IL300598A/en unknown
- 2021-08-17 EP EP21766347.5A patent/EP4196503A2/en active Pending
- 2021-08-17 AU AU2021329290A patent/AU2021329290A1/en not_active Abandoned
- 2021-08-17 TW TW110130298A patent/TW202214707A/zh unknown
- 2021-08-17 KR KR1020237009028A patent/KR20230048146A/ko not_active Withdrawn
- 2021-08-17 AR ARP210102304A patent/AR123266A1/es not_active Application Discontinuation
- 2021-08-17 JP JP2023511947A patent/JP7832926B2/ja active Active
- 2021-08-17 CA CA3191431A patent/CA3191431A1/en active Pending
- 2021-08-17 MX MX2023002002A patent/MX2023002002A/es unknown
- 2021-08-17 PE PE2023000289A patent/PE20230856A1/es unknown
- 2021-08-17 WO PCT/US2021/046217 patent/WO2022040128A2/en not_active Ceased
- 2021-08-17 CN CN202180066644.9A patent/CN116419925A/zh active Pending
-
2023
- 2023-02-16 CL CL2023000477A patent/CL2023000477A1/es unknown
- 2023-02-27 CO CONC2023/0002164A patent/CO2023002164A2/es unknown
- 2023-03-16 EC ECSENADI202318458A patent/ECSP23018458A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7826370B2 (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| US11685780B2 (en) | Single domain antigen binding domains that bind human Trop2 | |
| JP2022524337A5 (enExample) | ||
| JP2022524338A5 (enExample) | ||
| JP7832926B2 (ja) | 制約され、条件付きで活性化された結合タンパク質 | |
| WO2022061594A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2025512865A5 (enExample) | ||
| JP2025527303A (ja) | Ｉｌ－１８融合タンパク質およびｉｌ－１８を産生する方法 | |
| JP2025504909A5 (enExample) | ||
| JP7847284B1 (ja) | 上皮増殖因子受容体を標的とする組成物並びにその製造方法及び使用方法 | |
| Kim et al. | A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants | |
| US12128102B2 (en) | Constrained conditionally activated binding proteins | |
| US20230340159A1 (en) | Constrained conditionally activated binding proteins | |
| TW202304998A (zh) | 使用限制性條件活化之結合蛋白的治療方法 | |
| HK40032913A (en) | Constrained conditionally activated binding proteins | |
| JP2013177338A (ja) | トロポニンｉ結合タンパク質 |